Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity

Feijen, Elizabeth A M; Leisenring, Wendy; Stratton, Kayla; Ness, Kirsten K.; Pal, Helena J.H. van der; Dalen, Elvira C. van; Armstrong, Gregory T.; Aune, Gregory J.; Green, Daniel M.; Hudson, Melissa M.; Loonen, Jacqueline; Oeffinger, Kevin C.; Robison, Leslie L.; Yasui, Yutaka; Kremer, Leontien C. M.; Chow, Eric J.

doi:10.1001/jamaoncol.2018.6634

Cited by 182 publications

(140 citation statements)

References 47 publications

Supporting

Mentioning

137

Contrasting

Unclassified

Order By: Relevance

“…23 Mitoxantrone, an anthracenedione, appears to have a higher risk of ARLVD in comparison with doxorubicin. 24 In older adults, there is some evidence that the CAD needed to cause ARLVD is lower. 4,25 This was shown by the pivotal study of von Hoff et al 4 demonstrating higher incidences of ARLVD in adults .60 years even at lower CAD in comparison with younger adults (eg, incidence of ARLVD at a CAD of 250 mg/m 2 : 1.5% in adults aged 40-59 years vs 2.4% in adults aged $60 years; CAD of 400 mg/m 2 : 2.3% vs 4.6% and at 600 mg/m 2 14.9% vs 22.4%).…”

Section: Cadmentioning

confidence: 99%

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

et al. 2020

View full text Add to dashboard Cite

The incidence of acute myeloid leukemia (AML) increases with age. Intensive induction chemotherapy containing cytarabine and an anthracycline has been part of the upfront and salvage treatment of AML for decades. Anthracyclines are associated with a significant risk of cardiotoxicity (especially anthracycline-related left ventricular dysfunction [ARLVD]). In the older adult population, the higher prevalence of cardiac comorbidities and risk factors may further increase the risk of ARLVD. In this article of the Young International Society of Geriatric Oncology group, we review the prevalence of ARLVD in patients with AML and factors predisposing to ARLVD, focusing on older adults when possible. In addition, we review the assessment of cardiac function and management of ARLVD during and after treatment. It is worth noting that only a minority of clinical trials focus on alternative treatment strategies in patients with mildly declined left ventricular ejection fraction or at a high risk for ARLVD. The limited evidence for preventive strategies to ameliorate ARLVD and alternative strategies to anthracycline use in the setting of cardiac comorbidities are discussed. Based on extrapolation of findings from younger adults and nonrandomized trials, we recommend a comprehensive baseline evaluation of cardiac function by imaging, cardiac risk factors, and symptoms to risk stratify for ARLVD. Anthracyclines remain an appropriate choice for induction although careful risk-stratification based on cardiac disease, risk factors, and predicted chemotherapy-response are warranted. In case of declined left ventricular ejection fraction, alternative strategies should be considered.

show abstract

Section: Cadmentioning

confidence: 99%

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Unfortunately, the clinical utility of these effective agents is limited by their well-known cardiotoxic effects that can progress to end-stage heart failure [36]. Anthracyclines cause both acute and chronic cardiotoxic effects in pediatric cancer patients; however, lower anthracycline doses used in the recent treatment protocols have decreased the incidence of severe cardiovascular complications [37,38].…”

Section: Cardiotoxic Cancer Treatmentmentioning

confidence: 99%

Cardiovascular Vulnerability to COVID-19 in Cancer Survivors

Zordoky¹

2020

Preprint

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) has been declared a global pandemic by the World Health Organization on March 11, 2020. COVID-19 is caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-Cov-2). Although primarily a respiratory disease, cardiovascular complications of COVID-19 have been increasingly recognized. In addition, higher fatality has been reported in COVID-19 patients with underlying cardiovascular diseases. Cancer survivors have a considerably increased risk for premature cardiovascular diseases, mainly due to cardiotoxic cancer treatments. Therefore, it is foreseeable that cancer survivors will be more vulnerable to cardiovascular complications caused by COVID-19. In this review, three scenarios for increased cardiovascular complications of COVID-19 in cancer patients are proposed. In the first scenario, cardiotoxic cancer treatment and COVID-19 synergize to exacerbate direct myocardial damage. In the second scenario, cardiotoxic cancer treatment leads to a reduced cardiac reserve in cancer survivors, making them more vulnerable to COVID-19 in a “two-hit” model. The third scenario suggests that several shared risk factors may aggravate cardiovascular complications caused by both cancer treatment and COVID-19. Taken together, cancer survivors may be more vulnerable to cardiovascular complications when challenged by the COVID-19, and special cardiovascular care should be given to these patients.

show abstract

“…Таким образом происходит угнетение опухолевого роста и дальнейшего его развития. Данные группы препаратов благоприятны для лечения солидных опухолей [13]. Другой популярной мишенью для лечения рака является рецептор 2 эпидермального фактора роста человека (HER2).…”

Section: современная терапия неоплазииunclassified

Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods

Гумерова

Сахаутдинова

Полякова

2020

Kreativnaâ hirurgiâ i onkologiâ

View full text Add to dashboard Cite

Currently the oncological mortality takes the second place globally, the leading cause being cardiovascular diseases. The statistics of malignant neoplasms is rather negative all over the world. 10 million of cases of oncological disorders are diagnosed annually; this means that 27 million people fall sick with oncological diseases annually. It was established in 2019 that there are 14 million people suffering from oncological diseases, 8.2 million of these die. WHO anticipates that in 20 years’ time the malignant neoplasm incidence statistics will be on an increase as the number of new cases will reach 20 million, 12 million out of which will die. Regardless of such formidable figures medicine does not stand still; keeping up with the times, the science attempts to develop cutting edge methods of treating malignant tumours. As a result, the treatment of malignant neoplasms is continuing to improve. However, the number of side effects is also growing, thus requiring research attention. Therefore, the significance of the impact that oncological drugs have on a patient’s body is becoming more and more urgent for further discussion. While current tumour treatment methods involving drugs such as tyrosine kinase inhibitors, anthracycline chemotherapy and immunotherapy protocols are effective for the treatment of various forms of cancer, these drugs affect the DNA replication process thus resulting in endothelial dysfunction and nonspecific immune response. This causes cardiotoxic side effects. Cardiotoxicity, in its turn, is a notion that includes various adverse events involving the cardiovascular system of oncological patients receiving drug treatment. Cardiotoxicity may develop during treatment or following its completion.

show abstract

Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity

Cited by 182 publications

References 47 publications

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

Anthracycline-related cardiotoxicity in older patients with acute myeloid leukemia: a Young SIOG review paper

Cardiovascular Vulnerability to COVID-19 in Cancer Survivors

Antitumour Drug Induced Cardiovascular Toxicity and Current Tumour Treatment Methods

Contact Info

Product

Resources

About